1. Skyler,J.S., Brown,D., Chase,H.P., Collier,E., Cowie,C., Eisenbarth,G.S., Fradkin,J., Grave,G., Greenbaum,C., Jackson,R.A. et al. 2002. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N.Engl.J.Med. 346:1685-1691B.

2. Krischer,J.P., Cuthbertson,D.D., Yu,L., Orban,T., Maclaren,N., Jackson,R., Winter,W.E., Schatz,D.A., Palmer,J.P., and Eisenbarth,G.S. 2003. Screening strategies for the identification of multiple antibody-positive relatives of individuals with type 1 diabetes. J.Clin.Endocrinol.Metab 88:103-108.

3. Palmer,J.P., Asplin,C.M., Clemons,P., Lyen,K., Tatpati,O., Raghu,P.K., and Paquette,T.L. 1983. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 222:1337-1339.

4. Eisenbarth,G.S., Moriyama,H., Robles,D.T., Liu,E., Yu,L., Babu,S., Redondo,M., Gottlieb,P., Wegmann,D., and Rewers,M. 2002. Insulin autoimmunity: prediction/precipitation/prevention type 1A diabetes. Autoimmun.Rev. 1:139-145.

5. Haskins,K. and Wegmann,D. 1996. Diabetogenic T-cell clones. Diabetes 45:1299-1305.

6. Lombardo,F., Valenzise,M., Wasniewska,M., Messina,M.F., Ruggeri,C., Arrigo,T., and De Luca,F. 2002. Two-year prospective evaluation of the factors affecting honeymoon frequency and duration in children with insulin dependent diabetes mellitus: the key-role of age at diagnosis. Diabetes Nutr.Metab 15:246-251.

7. Shah,S.C., Malone,J.I., and Simpson,N.E. 1989. A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus. N.Engl.J Med 320:550-554.

8. 1998. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann.Intern Med 128:517-523.

9. Landin-Olsson,M. 2002. Latent autoimmune diabetes in adults. Ann.N.Y.Acad.Sci. 958:112-116.

10. Tuomi,T., Groop,L.C., Zimmet,P.Z., Rowley,M.J., Knowles,W., and Mackay,I.R. 1993. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 42:359-362.

11. Falorni,A. and Calcinaro,F. 2002. Autoantibody profile and epitope mapping in latent autoimmune diabetes in adults. Ann.N.Y.Acad.Sci. 958:99-106.

12. Zimmet,P.Z., Tuomi,T., Mackay,I.R., Rowley,M.J., Knowles,W., Cohen,M., and Lang,D.A. 1994. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet.Med. 11:299-303.

13. Haist, R. E, Campbell, J, and Best, C. H. The prevention of diabetes. N.Engl.J Med 223, 607-615. 1940.

Ref Type: Journal (Full)

14. Stiller,C.R., Dupre,J., Gent,M., Jenner,M.R., Keown,P.A., Laupacis,A., Martell,R., Rodger,N.W., Graffenried,B.V., and Wolfe,B.M.J. 1984. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 223:1262-1367.

15. Assan,R., Feutren,G., and Sirmai,J. 1988. Cyclosporine trials in diabetes: Updated results of the French experience. Transplant.Proc. 20 Suppl. 3:178-183.

16. Cohen,I.R. 1992. Immunologically specific treatment of spontaneous insulin- dependent diabetes mellitus of NOD mice. J.Autoimmun. 5 Suppl A:227-230.

17. 1988. Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. The Canadian-European Randomized Control Trial Group. Diabetes 37:1574-1582.

18. Assan,R., Feutren,G., Sirmai,J., Laborie,C., Boitard,C., Vexiau,P., Du,R.H., Rodier,M., Figoni,M., Vague,P. et al. 1990. Plasma C-peptide levels and clinical remissions in recent-onset type I diabetic patients treated with cyclosporin A and insulin. Diabetes 39:768-774.

19. Cook,J.J., Hudson,I., Harrison,L.C., Dean,B., Colman,P.G., Werther,G.A., Warne,G.L., and Court JM. 1989. Double-blind controlled trial of azathioprine in children with newly diagnosed type I diabetes. Diabetes 38:779-783.

20. Silverstein,J., Maclaren,N., Riley,W., Spillar,R., Radjenovic,D., and Johnson,S. 1988. Immunosuppression with azathioprine and prednisone in recent- onset insulin-dependent diabetes mellitus. N.Engl.J.Med. 319:599-604.

21. Herold,K.C., Hagopian,W., Auger,J.A., Poumian-Ruiz,E., Taylor,L., Donaldson,D., Gitelman,S.E., Harlan,D.M., Xu,D., Zivin,R.A. et al. 2002. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N.Engl.J.Med. 346:1692-1698.

22. Harrison,L.C., Colman,P.G., Dean,B., Baxter,R., and Martin,F.I. 1985. Increase in remission rate in newly diagnosed type I diabetic subjects treated with azathioprine. Diabetes 34:1306-1308.

23. Raz,I., Elias,D., Avron,A., Tamir,M., Metzger,M., and Cohen,I.R. 2001. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 358:1749-1753.

24. Panto,F., Giordano,C., Amato,M.P., Pugliese,A., Donatelli,M., D'Acquisto,G., and Galluzzo,A. 1990. The influence of high dose intravenous immunoglobulins on immunological and metabolic pattern in newly diagnosed type I diabetic patients. J Autoimmun. 3:587-592.

25. Coutant,R., Landais,P., Rosilio,M., Johnsen,C., Lahlou,N., Chatelain,P., Carel,J.C., Ludvigsson,J., Boitard,C., and Bougneres,P.F. 1998. Low dose linomide in Type I juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial. Diabetologia 41:1040-1046.

26. Secchi,A., Pastore,M.R., Sergi,A., Pontiroli,A.E., and Pozza,G. 1990. Prednisone administration in recent onset type I diabetes. J Autoimmun. 3:593-600.

27. Gale,E.A. 2003. Intervening before the onset of Type 1 diabetes: baseline data from the European Nicotinamide Diabetes Intervention Trial (ENDIT). Diabetologia 46:339-346.

28. Carel,J.C. and Bougneres,P.F. 1996. Treatment of prediabetic patients with insulin: experience and future. European Prediabetes Study Group. Horm.Res. 45 Suppl 1:44-47.

29. Buckingham,B.A. and Sandborg,C.I. 2000. A randomized trial of methotrexate in newly diagnosed patients with type 1 diabetes mellitus. Clin.Immunol. 96:86-90.

30. Greenbaum, C. Type 1 Diabetes Intervention Trials: What have we learned? A critical review of selected intervention trials. Clin.Immunol. 104(2), 97-104. 2002.

31. Couzin,J. 2003. Clinical trials. Diabetes' brave new world. Science 300:1862-1865.

32. Greenbaum,C.J., Cuthbertson,D., and Krischer,J.P. 2001. Type I diabetes manifested solely by 2-h oral glucose tolerance test criteria. Diabetes 50:470-476.

33. Grodsky,G.M., Feldman,R., Toreson,W.E., and Lee,J.C. 1966. Diabetes mellitus in rabbits immunized with insulin. Diabetes 15:579-585.

34. Herold,K.C., Hagopian,W., Auger,J.A., Poumian-Ruiz,E., Taylor,L., Donaldson,D., Gitelman,S.E., Harlan,D.M., Xu,D., Zivin,R.A. et al. 2002. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N.Engl.J Med 346:1692-1698.

35. Chatenoud,L., Thervet,E., Primo,J., and Bach,J.F. 1994. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc.Natl.Acad.Sci.U.S.A 91:123-127.

36. Herold,K.C., Bluestone,J.A., Montag,A.G., Parihar,A., Wiegner,A., Gress,R.E., and Hirsch,R. 1992. Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes 41:385-391.

37. Masteller,E.L. and Bluestone,J.A. 2002. Immunotherapy of insulin-dependent diabetes mellitus. Curr.Opin.Immunol. 14:652-659.

38. 2003. Prevention of Type 1 Diabetes Mellitus. Diabetes Care 26:140S.

39. Greenbaum,C.J. and Harrison,L.C. 2003. Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes. Diabetes 52:1059-1065.

40. 2002. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care 25:2165-2171.

41. Eriksson,J., Lindstrom,J., Valle,T., Aunola,S., Hamalainen,H., Ilanne-Parikka,P., Keinanen-Kiukaanniemi,S., Laakso,M., Lauhkonen,M., Lehto,P. et al. 1999. Prevention of Type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1-year interim report on the feasibility of the lifestyle intervention programme. Diabetologia 42:793-801.

42. Zimmet,P., Shaw,J., and Alberti,K.G.M.M. 2003. Preventing Type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view. Diabet Med 20:693-702.

43. 2003. Screening for type 2 diabetes. Diabetes Care 26 Suppl 1:S21-S24.

44. Menser,M.A., Dods,L., and Harley,J.D. 1967. A twenty-five-year follow-up of congenital rubella. Lancet 2:1347-1350.

45. McIntosh,E.D. and Menser,M.A. 1992. A fifty-year follow-up of congenital rubella. Lancet 340:414-415.

46. Robles,D.T. and Eisenbarth,G.S. 2001. Type 1A diabetes induced by infection and immunization. J Autoimmun. 16:355-362.

47. Karounos,D.G., Wolinsky,J.S., and Thomas,J.W. 1993. Monoclonal antibody to rubella capsid protein recognizes a beta cell antigen. J.Immunol. 150:3080-3085.

48. Danovaro-Holliday,M.C., LeBaron,C.W., Allensworth,C., Raymond,R., Borden,T.G., Murray,A.B., Icenogle,J.P., and Reef,S.E. 2000. A large rubella outbreak with spread from the workplace to the community. JAMA 284:2733-2739.

49. Paul,M.O. and Paul,B.D. 1983. Comparative sero-epidemiologic observations of rubella infection in pregnant women and female university students. J Hyg.Epidemiol.Microbiol.Immunol. 27:179-183.

50. Francis,B.H., Thomas,A.K., and McCarty,C.A. 2003. The impact of rubella immunization on the serological status of women of childbearing age: a retrospective longitudinal study in Melbourne, Australia. Am.J Public Health 93:1274-1276.

51. Schoenhoff,D.D., Lane,T.W., and Hansen,C.J. 1997. Primary prevention and rubella immunity: overlooked issues in the outpatient obstetric setting. Infect.Control Hosp.Epidemiol. 18:633-636.

52. Watson,J.C., Hadler,S.C., Dykewicz,C.A., Reef,S., and Phillips,L. 1998. Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm.Rep. 47:1-57.